March 13, 2026

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Conexiant

March 10, 2026

Not All COPD Is Smoking-Related

Study compares symptoms, spirometry, and inflammatory markers with smoking-related disease.

Conexiant

March 10, 2026

Singing Program Feasible After Pulmonary Rehabilitation

Study finds 12-week singing intervention feasible following pulmonary rehabilitation, supporting larger trial.

Conexiant

March 10, 2026

Psilocybin Beats Nicotine Patch in Smoking Trial

A single psilocybin dose outperforms standard nicotine replacement, opening a new front in one of medicine’s most intractable problems.

Conexiant

February 19, 2026

Quality of Life in Cardiac Arrest Recovery

Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.

Conexiant

February 19, 2026

COPD Clinical Trials at Temple Lung Center

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity, and many patients continue to experience symptoms despite optimal therapy. As one of the world’s largest and most experienced COPD research programs, the Temple Lung Center offers access to clinical trials evaluating new pharmacologic, device-based, and comprehensive treatment approaches.

Temple Health

February 18, 2026

COPD: CT Imaging Aligns With Eosinophils

Quantitative imaging and lab data reveal patterns in chronic obstructive pulmonary disease.

Conexiant

February 13, 2026

Chronic Cough Despite Normal Workup

Researchers describe diagnostic evaluation and management considerations when standard testing fails to identify the cause of persistent cough.

Conexiant

January 27, 2026

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Conexiant

December 13, 2024

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Conexiant